$SCYX I wasn't expecting it to sit comfortably in the 1.30s. I don't think positive trial results or conferences do very much with this one of recent. The effectiveness of Ibrexafungerp on candidiasis is all I care about. That's the one tool they have that can make this thing swing hard. I project that an NDA filing or a significant media coverage event is what's going to give this thing more momentum. The only people really tracking phase trial data are people who are already long (and maybe a few swing traders). After all, every trial result is just reaffirmation of what we already know: "Ibrexfungerp works damn well and is continuing to work damn well". Yeah we know it works, now let's get on with it.
  • 4